Cardiovascular Systems Inc. (CSII)

51.63
NASDAQ : Health Technology
Prev Close 50.87
Day Low/High 49.27 / 52.02
52 Wk Low/High 24.84 / 52.13
Avg Volume 306.20K
Exchange NASDAQ
Shares Outstanding 35.27M
Market Cap 1.80B
P/E Ratio N/A
Div & Yield N.A. (N.A)
New Reimbursement Codes Introduced To Better Track Costs Of Treating Patients With Severely Calcified Lesions

New Reimbursement Codes Introduced To Better Track Costs Of Treating Patients With Severely Calcified Lesions

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) today announced new medical diagnosis and procedure codes for severely calcified coronary arteries.

Cardiovascular Systems’ Peripheral And Coronary Data From Six Studies Presented At TCT

Cardiovascular Systems’ Peripheral And Coronary Data From Six Studies Presented At TCT

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), yesterday presented six-month data from the COMPLIANCE 360° study of severely calcified above-the-knee lesions at the 23rd Annual Transcatheter Cardiovascular ...

Cardiovascular Systems To Present Peripheral And Coronary Data From Six Studies At TCT

Cardiovascular Systems To Present Peripheral And Coronary Data From Six Studies At TCT

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), will present six-month data from the COMPLIANCE 360° study of severely calcified above-the-knee lesions at the 23 rd Annual Transcatheter Cardiovascular...

Cardiovascular Systems Reports Fiscal 2012 First-Quarter Financial Results

Cardiovascular Systems Reports Fiscal 2012 First-Quarter Financial Results

Cardiovascular Systems, Inc. (Nasdaq: CSII): Financial performance improved over prior-year first quarter and aligned with pre-release: Revenues increased 3 percent...

Cardiovascular Systems To Webcast Fiscal 2012 First-Quarter Earnings Conference Call Wednesday, November 2

Cardiovascular Systems To Webcast Fiscal 2012 First-Quarter Earnings Conference Call Wednesday, November 2

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) will host a live webcast of its fiscal 2012 first-quarter conference call on Wednesday, November 2, 2011, at 3:45 p.

Insiders Trading STZ, CSII, CWTR, VMI

Insiders Trading STZ, CSII, CWTR, VMI

The top 10 open-market insider purchases and sales filed at the SEC Thursday.

Cardiovascular Systems’ Predator 360° Data Demonstrates Favorable 12-Month Results Treating Peripheral Arterial Disease

Cardiovascular Systems’ Predator 360° Data Demonstrates Favorable 12-Month Results Treating Peripheral Arterial Disease

Data from Cardiovascular Systems’ (CSI) (Nasdaq: CSII) Predator 360° prospective single-center clinical study titled, Use of Orbital Treatment in a High Volume Clinical Practice Modifies Non-Compliant Plaque...

Insiders Trading CSII, ACAS, ENTG, QCOM

Insiders Trading CSII, ACAS, ENTG, QCOM

The top 10 open-market insider purchases and sales filed at the SEC Wednesday.

Cardiovascular Systems Stock Gaps Down On Today's Open (CSII)

Cardiovascular Systems Stock Gaps Down On Today's Open (CSII)

Shares of Cardiovascular Systems (Nasdaq:CSII) were gapping down Friday morning with an open price 10.4% lower than Thursday's closing price. The stock closed at $10.30 yesterday and opened today's trading at $9.23.

Cardiovascular Systems Announces Preliminary First-Quarter Financial Results

Cardiovascular Systems Announces Preliminary First-Quarter Financial Results

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today announced preliminary revenue of...

Cardiovascular Systems To Present At Three September Investor Conferences

Cardiovascular Systems To Present At Three September Investor Conferences

Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device company developing and commercializing innovative, interventional treatment systems for vascular and coronary disease, will present at three upcoming...

Cardiovascular Systems Inc. Stock Upgraded (CSII)

Cardiovascular Systems Inc. Stock Upgraded (CSII)

Cardiovascular Systems (Nasdaq:CSII) has been upgraded by TheStreet Ratings from a sell to hold.

Cardiovascular Systems Reports Fiscal 2011 Fourth-Quarter And Full-Year Financial Results

Cardiovascular Systems Reports Fiscal 2011 Fourth-Quarter And Full-Year Financial Results

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) Financial performance rose significantly over prior-year fourth quarter: Revenues increased 20 percent to $21.

Cardiovascular Systems To Webcast Fiscal 2011 Fourth-Quarter Earnings Conference Call Wednesday, August 3

Cardiovascular Systems To Webcast Fiscal 2011 Fourth-Quarter Earnings Conference Call Wednesday, August 3

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) will host a live webcast of its fiscal 2011 fourth-quarter conference call on Wednesday, August 3, 2011, at 3:45 p.

Cardiovascular Systems Added To Russell 2000® Index

Cardiovascular Systems Added To Russell 2000® Index

Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, has been added to the...

Cardiovascular Systems Presents New Acute And Long-Term Data From Three Peripheral Clinical Studies

Cardiovascular Systems Presents New Acute And Long-Term Data From Three Peripheral Clinical Studies

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), announced data highlighting the advantages of its Diamondback and Predator 360 ® PAD Systems at the New Cardiovascular Horizons (NCVH) meeting in New Orleans.

Cardiovascular Systems Announces Filing Of Universal Shelf Registration Statement

Cardiovascular Systems Announces Filing Of Universal Shelf Registration Statement

Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII) announced today that it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC).

Cardiovascular Systems Receives FDA Approval To Complete Patient Enrollment In ORBIT II Coronary Clinical Trial

Cardiovascular Systems Receives FDA Approval To Complete Patient Enrollment In ORBIT II Coronary Clinical Trial

Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) has received FDA approval to complete enrollment of 429 patients in its ORBIT II Investigational Device Exemption (IDE) clinical trial for a coronary application for its...

Cardiovascular Systems Names Kevin J. Kenny Executive Vice President Of Sales And Marketing

Cardiovascular Systems Names Kevin J. Kenny Executive Vice President Of Sales And Marketing

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) has named Kevin J.

Cardiovascular Systems To Present At 10th Annual JMP Securities Research Conference On Tuesday, May 10

Cardiovascular Systems To Present At 10th Annual JMP Securities Research Conference On Tuesday, May 10

Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device company developing and commercializing innovative, interventional treatment systems for vascular disease, will present at the 10 th Annual JMP Securities...

Cardiovascular Systems Reports Fiscal 2011 Third-Quarter Financial Results

Cardiovascular Systems Reports Fiscal 2011 Third-Quarter Financial Results

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII): Financial performance rose significantly over prior-year third quarter: Revenues increased 22 percent to $20.

Cardiovascular Systems To Webcast Fiscal 2011 Third-Quarter Earnings Conference Call Wednesday, May 4

Cardiovascular Systems To Webcast Fiscal 2011 Third-Quarter Earnings Conference Call Wednesday, May 4

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) will host a live webcast of its fiscal 2011 third-quarter conference call on Wednesday, May 4, 2011, at 3:45 p.

Cardiovascular Systems’ COMPLIANCE 360° Trial Demonstrates Superior Acute Results Of The Diamondback 360° Over Balloon Angioplasty

Cardiovascular Systems’ COMPLIANCE 360° Trial Demonstrates Superior Acute Results Of The Diamondback 360° Over Balloon Angioplasty

Acute data from Cardiovascular Systems’ (CSI) (Nasdaq: CSII) prospective, randomized COMPLIANCE 360° clinical trial was presented today at the American College of Cardiology’s (ACC) 60 th Scientific...

The Diamond-coated Crowns Include Solid And Classic Configurations And Are Designed To Remove Hardened Plaque Efficiently. (Photo: Business Wire)

The Diamond-coated Crowns Include Solid And Classic Configurations And Are Designed To Remove Hardened Plaque Efficiently. (Photo: Business Wire)

Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII) has received 510(k) marketing clearance from the U.

Cardiovascular Systems To Present At Upcoming Investor Conferences

Cardiovascular Systems To Present At Upcoming Investor Conferences

Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device company developing and commercializing innovative, interventional treatment systems for vascular disease, will present at two upcoming health care ...

Cardiovascular Systems Files Special 510(k) For Stealth 360°™ Orbital Pad System

Cardiovascular Systems Files Special 510(k) For Stealth 360°™ Orbital Pad System

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), has filed a Special 510(k) application with the U.

Cardiovascular Systems Reports Fiscal 2011 Second-Quarter Financial Results

Cardiovascular Systems Reports Fiscal 2011 Second-Quarter Financial Results

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII): Financial performance improved significantly over prior-year second quarter: Revenue increased 24 percent to $18.

Cardiovascular Systems To Webcast Fiscal 2011 Second-Quarter Earnings Conference Call Wednesday, February 2

Cardiovascular Systems To Webcast Fiscal 2011 Second-Quarter Earnings Conference Call Wednesday, February 2

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) will host a live webcast of its fiscal 2011 second-quarter conference call on Wednesday, February 2, 2011, at 3:45 p.

Cardiovascular Systems Reports Fiscal 2011 First-Quarter Financial Results

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII): Financial performance improved significantly over prior year’s first quarter Revenue increased 20 percent to...

TheStreet Quant Rating: C (Hold)